Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the shares of Allergy Therapeutics plc. On August 11, 2023, the company purchased 37,946 0.1p ordinary shares at a price of 0.02415 per unit and sold 20,000 0.1p ordinary shares at a price of 0.02525 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. No indemnity or option arrangements were disclosed, and there were no agreements or understandings relating to options or derivatives. The disclosure was made in accordance with Rule 8 of the Takeover Code.